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Background: Y-box binding protein-1 is an evolutionary conserved transcription and translation regulating protein
that is overexpressed in various human malignancies, including breast cancer. Despite reports of YB-1 and its
association with distant spread of breast cancer, the intrinsic mechanism underlying this observation remains
elusive. This study investigates the role of YB-1 in mediating metastasis in highly invasive breast cancer cell lines.
Methods: Silencing the YBX1 gene (which encodes the YB-1 protein) by small interfering RNA (siRNA) was
performed in MDA-MB-231 and Hs578T breast cancer cell lines, followed by phenotypic assays including cell
migration and invasion assays. Gene expression profiling using Affymetrix GeneChip® Human Transcriptome 2.0
array was subsequently carried out in YB-1 silenced MDA-MB-231 cells. Overexpression and silencing of YBX1 were
performed to assess the expression of CORO1C, one of the differentially regulated genes from the transcriptomic
analysis. A Gaussia luciferase reporter assay was used to determine if CORO1C is a putative YB-1 downstream target.
siRNA-mediated silencing of CORO1C and down-regulation of YBX1 in CORO1C overexpressing MDA-MB-231 cells
were performed to evaluate cell migration and invasion.
Results: Downregulation of the YB-1 protein inhibited cell migration and invasion in MDA-MB-231 breast cancer
cells. Global gene expression profiling in the YBX1 silenced MDA-MB-231 cells identified differential expression of
several genes, including CORO1C (which encodes for an actin binding protein, coronin-1C) as a potential downstream
target of YB-1. While knockdown of YBX1 gene decreased CORO1C gene expression, the opposite effects were seen in
YB-1 overexpressing cells. Subsequent verification using the reporter assay revealed that CORO1C is an indirect
downstream target of YB-1. Silencing of CORO1C by siRNA in MDA-MB-231 cells was also observed to reduce
cell migration and invasion. Silencing of YBX1 caused a similar reduction in CORO1C expression, concomitant
with a significant decrease in migration in Hs578T cells. In coronin-1C overexpressing MDA-MB-231 cells,
increased migration and invasion were abrogated by YB-1 knockdown.
Conclusion: It would appear that YB-1 could regulate cell invasion and migration via downregulation of its
indirect target coronin-1C. The association between YB-1 and coronin-1C offers a novel approach by which
metastasis of breast cancer cells could be targeted and abrogated.
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Breast cancer is the leading cancer that affects women
around the world, where the majority of deaths due to
this dreaded disease could be attributed to metastasis.
The World Health Organisation (WHO) has ranked
breast cancer as the most common cause of cancer-
related deaths in women in 2012, accounting for
approximately 14.3% of cancer-related mortality in less
developed countries [1]. Metastasis involves the invasion
of cancer cells from the primary tumour site to the
surrounding extracellular matrix and stroma, from
wherein the cancer cells intravasate, travel through the
vasculature and extravasate to form a secondary tumour
at a distant site [2]. It is estimated that approximately
10–15% of breast cancer patients, show evidence of
distant metastasis within 3 years from the initial detec-
tion of the primary tumour [3]. However, in some breast
cancer patients, metastasis occurs after 10 years from
the initial presentation of the primary tumour [4].
Furthermore, the heterogeneous nature of breast cancer
makes it difficult for identification of patients who are at
risk of developing metastasis.
Recent research has shed light on a potential bio-
marker for early metastasis, namely Y-box binding
protein-1 (YB-1) encoded by the YBX1 gene. YB-1 is an
evolutionary conserved protein with a cold-shock do-
main, and is crucial to many fundamental cellular pro-
cesses, including transcription and translation regulation
[5]. Elevated YB-1 has been observed in many human
malignancies, such as prostate cancer [6], gastric cancer
[7, 8] and nasopharyngeal cancer [9]. YB-1 overexpres-
sion has been found be an independent prognostic
marker in breast cancer [10]. Overexpression of YB-1 in
the mammary gland of a novel transgenic mouse model
showed that YB-1 induced genetic instability, leading to
breast cancer [11]. In addition, YB-1 is involved in the
upregulation of the transcription of multidrug resistance
1 (MDR1) gene which encodes for P-glycoprotein, a pro-
tein which mediates chemoresistance [12, 13]. YB-1 also
contributes to enhanced membrane type I-matrix
metalloproteinase (MT1-MMP) activity in MCF7 breast
cancer cells, thus inducing tumor invasion and metasta-
sis [14]. Moreover, YB-1 has been observed to potentiate
epithelial to mesenchymal transition (EMT), possibly
through the elevated translation of Snail1, which is an
important mediator of the EMT process, and eventually
leading to enhanced metastasis [15].
This study attempts to elucidate the role of YB-1
in mediating the metastatic cascade, through manipula-
tion of YB-1 expression in aggressive MDA-MB-231 and
Hs578T breast cancer cells. Gene expression profiling
revealed that knockdown of YB-1, inhibited migratory
and invasive potential with altered expression of several
genes, in invasive MDA-MB-231 cells. Functional annotationclustering using the DAVID analysis, demonstrated
that these differentially expressed genes are important
for the cytoskeletal pathway, including CORO1C
which encodes coronin-1C, an actin-binding protein.
siRNA mediated silencing of CORO1C in MDA-MB-
231 cells was observed to decrease cell migration and
invasion (similar to YB-1 silenced cells). Similar find-
ings were also observed in Hs578T breast cancer cells.
Furthermore, transient overexpression of coronin-1C
resulted in increased cell migration and invasion, which
was abrogated by YB-1 knockdown in MDA-MB-231
cells. We show for the first time that YB-1 could regulate




The human MDA-MB-231 breast cancer cell line (ATCC®
HTB-26™) was cultured in RPMI 1640 medium, which
contained 10% fetal bovine serum (FBS). Hs578T breast
cancer cells (ATCC® HTB-126™) were propagated in
DMEM medium with 10% FBS and supplemented with
50 μg/ml insulin (Sigma-Aldrich, St. Louis, MO, USA).
Short interfering RNA (siRNA) transfection
2.5 × 105 MDA-MB-231 cells and 1 × 105 Hs578T cells
were seeded in each well of a 6-well plate, a day prior to
siRNA transfection. The ON-TARGETplus SMARTpool
siRNA (GE Dharmacon, Pitssburgh, PA, USA), con-
sisting of 4 individual siRNA targeting YBX1 or
CORO1C were used. A non-targeting siRNA was used
as the negative control (siNeg). Triplicate wells were
seeded for each of the siRNA. The transfection was
carried out following the manufacturer’s protocol.
Briefly, a final concentration of 20 nM for each of the
siRNA was added together with the transfection re-
agent DharmaFECT (GE Dharmacon). The cells, to-
gether with the transfection mixture were incubated
for 24 h, after which they were replenished with fresh
medium. Cells were grown for 48 h and 72 h after
transfection for RNA extraction and protein extrac-
tion respectively.
Quantitative real-time polymerase chain reaction (qPCR)
After extraction of total RNA with the RNeasy Mini
extraction kit (Qiagen, Hilden, Germany), 1 μg of total
RNA was converted to first strand cDNA using the
SuperScript III First-Strand synthesis system (Invitrogen,
Carlsbad, CA, USA). Gene expression of YBX1 and
CORO1C were subsequently quantified in an Applied
Biosystems 7900HT Fast Real-Time PCR system using
the Fast SYBR Green Master Mix (Applied Biosystems,
Foster City, CA, USA). Each sample was run in tripli-
cates and GAPDH was used as the housekeeping gene
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expressed as fold change using the 2-ΔΔCT method [16].
The primers used are listed in Additional file 1: Table S1.
Western blot
Whole cell lysates were extracted using a mixture of
radio-immunoprecipitation (RIPA) lysis buffer (Pierce,
Waltham, MA, USA), Halt Protease and Phosphatase In-
hibitor Cocktail (Pierce) and 0.5 ethylenediaminetetra-
acetic acid (EDTA) (Pierce) on ice for 15 min. After cell
lysis, the lysates were centrifuged for 15 min at 21,000 g,
4 °C. Protein concentration was determined using the
microtiter Bio-Rad Protein Assay (Bio-Rad, Hercules,
CA, USA). The same amount of protein lysates were de-
natured at 95 °C in 5X loading dye for 5 min and loaded
into each well of the 10% sodium dodecyl sulfate-
polyacrylamide gel. After separation by electrophoresis,
proteins were transferred to a polyvinyl difluoride
(PVDF) membrane using a semi-dry system (Bio-Rad).
Transfer of proteins was carried out at 20 V for 1 h.
Blocking of the PVDF membrane was subsequently done
using 5% skim milk, followed by incubation with pri-
mary antibodies that include anti-coronin-1C (1:1000 di-
lution) (Abnova, Taipei City, Taiwan), anti-HIPK3
(1:5000) (Abcam, Cambridge, UK), anti-SLAIN2 (1:1000
dilution) (Abcam), anti-YB-1 (1:1000 dilution) [9] and
anti-β-actin (1:6000 dilution) (Sigma-Aldrich) at 4 °C
overnight. Subsequently, incubation with the HRP-
conjugated secondary antibody (Sigma-Aldrich) was car-
ried out for 1 h at room temperature. The SuperSignal
West Pico Chemiluminescent ECL substrate (Pierce)
was used to detect the protein bands which were then
quantified using the GS-800 densitometer (Bio-Rad).
Cell migration and cell invasion assays
Transwell migration assay was performed by using poly-
carbonate membrane transwell inserts (Corning, NY,
USA), with a membrane diameter of 8.0 μm. A BD Bio-
Coat™ Matrigel™ Invasion Chamber (BD Biosciences, San
Jose, CA, USA) with an 8 μm pore size Polyethylene
Terephthalate membrane, was used for the cell invasion
assay. 48 h post-transfection with siRNA, 20,000 cells/
well or 30,000 cells/well were seeded in triplicates in the
upper chamber for the transwell migration or invasion
respectively for MDA-MB-231 cells. For Hs578T cells,
10,000 cells/well and 20,000 cells/well were seeded and
incubated for 18 h or 20 h, for the migration and inva-
sion assays respectively. After which, the migratory or
invasive cells were fixed with absolute methanol for
15 min, washed twice and stained with 0.5% crystal vio-
let in water for 20 min. Removal of excess crystal violet
stain was carried out by dipping the upper chamber in-
serts in distilled water and wiped away with cotton
swabs from the upper membrane of the inserts. A NikonSMZ 1500 stereo microscope at 10X magnification was sub-
sequently used to view the stained cells. Five different fields
were imaged and the average number of cells per insert was
counted. Experiments were performed in triplicates.
Gene microarray
To determine potential targets of YB-1 in MDA-MB-231
cells, global gene expression profiling was performed using
Affymetrix GeneChip® Human Transcriptome 2.0 Array
(Affymetrix, Santa Clara, CA, USA). Briefly, 100 ng of
RNA was reverse transcribed to generate double stranded
cDNA that was amplified to produce cRNA. The cRNA
generated was purified and subjected to 2nd –cycle single
stranded sense cDNA that was fragmented, labelled and
hybridized to Affymetrix GeneChip® Human Transcrip-
tome 2.0 array. The arrays were washed, stained and
scanned using the Affymetrix 3000 7G scanner. The differ-
entially expressed genes between siNeg and siYB-1 trans-
fected cells were determined using a fold change cut-off at
2 and p < 0.05 with the Transcriptome Analysis Console
3.0 software and annotation file HTA-2_0.na36.hg19.tran-
script.csv available from Affymetrix. Functional annotation
clustering of the differentially expressed genes was carried
out using the Database for Annotation, Visualization and
Integrated Discovery (DAVID).
Transfection of YB-1 overexpression plasmid
A cell density of 2.5 × 105 MDA-MB-231 cells was plated
in each well of a 6-well plate, a day prior to plasmid trans-
fection. The following day, the cells were transfected with
2 μg of pCMV6-AC-YBX1-GFP overexpression plasmid
which encodes the ORF of YBX1 gene (Origene, Rockville,
MD, USA) or the pCMV6-AC-GFP empty vector control
(Origene) using 6 μl of TurboFectin 8.0 (Origene) per
well. The transfected cells were then incubated for 72 h
for protein isolation. Experiments were performed in trip-
licate wells for each plasmid.
Gaussia luciferase reporter assay
Gaussia luciferase reporter constructs containing the
promoter region of CORO1C gene and a negative pro-
moter region (both from Genecopoeia, Rockville, MD,
USA) were used. 2.5 × 105 MDA-MB-231 cells were
seeded per well in a 6-well plate and co-transfected with
20 nM of siNeg or siYB-1 with 1 μg of CORO1C pro-
moter reporter construct, using Lipofectamine 2000
(Invitrogen). Also, 1 μg of negative promoter construct
was used in place of the CORO1C promoter reporter
construct and co-transfected with 20 nM of siYB-1. The
co-transfections were done in triplicates. Media was
changed 24 h post transfection. Subsequently, the cell
culture supernatant was collected from each well 48 h
post transfection and the Gaussia luciferase (GLuc) and
secreted alkaline phosphatase (SEAP) activities were
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Assay Kit (Genecopoeia), in triplicates with 1500 ms in-
tegration time. Normalised data (relative luminescence
unit, RLU) was calculated as the ratio of GLuc/SEAP ac-
tivities from the triplicate readings. The average RLU
was calculated from an average of the normalised data
for the triplicate transfected wells.
In addition, MDA-MB-231 cells were co-transfected
with 1 μg of CORO1C promoter reporter construct and
1 μg of YB-1 ORF construct (pCMV6-AC-YBX1-GFP) or
empty vector construct (pCMV6-AC-GFP) in a 6-wellFig. 1 YBX1 silencing in MDA-MB-231 cells reduced cell migration and cell in
1 protein expression in YB-1 silenced MDA-MB-231 cells and a representative
siRNA and alterations in cell migration and invasion were determined using t
cates statistically significant difference. Representative fields of the migration aplate using TurboFectin 8.0 (Origene), in accordance
with the manufacturer’s protocol. 1 μg of negative pro-
moter construct was also used in place of CORO1C pro-
moter reporter construct and co-transfected with 1 μg of
YB-1 ORF plasmid. After which, the same procedure as
mentioned above was repeated.
Co-transfection of siRNA and plasmid DNA
6 × 104 MDA-MB-231 cells were seeded in each well of
a 24-well plate. The following day, cells were transfected
with 200 ng of pCMV6-AC-GFP empty vector controlvasion. a YBX1 gene expression in YB-1 silenced MDA-MB-231 cells. b YB-
image of the Western blot. c-d MDA-MB-231 cells were transfected with
ranswell inserts. Error bar = SEM, *p < 0.05, **p < 0.01, ***p < 0.001 indi-
nd invasion assay at 10X magnification are shown (Scale bar =100 μm)
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CORO1C-GFP) (Origene) with 1μl of Lipofectamine
3000 and 0.8μl of P3000 (Invitrogen), according to the
manufacturer’s protocol and incubated overnight. Subse-
quently, the cells were transfected with siNeg or siYB-1
siRNA to a final concentration of 20 nM per well using
DharmaFECT (GE Dharmacon) as described above. The
cells were incubated for an additional of 48 h before
seeding for migration or invasion assay.
Statistical analyses
The GraphPad Prism 5.0 was used for analyses. Data
was analyzed with two-sided unpaired Student’s t-testFig. 2 YBX1 silencing in Hs578T cells inhibited cell migration but not cell invasio
level and protein expression of YB-1. c-d YBX1 silenced cells showed a a concomi
bar = SEM, ** p < 0.01, ***p < 0.001. Representative fields of the migration and infor samples with two groups and One-way ANOVA for
samples with more than two groups. All values are rep-
resented as mean ± SEM. The results were considered
statistically significant when p is <0.05.
Results
Downregulation of YB-1 protein decreased cell migration
and invasion
To evaluate YB-1 function in breast cancer metastasis,
silencing of the YBX1 gene by siRNA was carried out in
MDA-MB-231 breast cancer cells. The silencing eff-
ciency of the YBX1 gene was approximately 85.1% in the
siYB-1 cells (Fig. 1a), while at the protein level, YB-1n. a-b Knockdown of YBX1 in Hs578T breast cancer cells decreased gene
tant reduction in cell migration and a downward trend for cell invasion. Error
vasion assay at 10X magnification are shown as well (Scale bar =100 μm)
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significant decrease in cell migration (approximately
21.2%) (Fig. 1c) and cell invasion (55.5%) (Fig. 1d) were
observed in the YBX1 silenced MDA-MB-231 cells when
compared to control (siNeg) cells.
The findings were also validated in invasive Hs578T
breast cancer cells. The YB-1 transcript and protein level
were successfully down-regulated following transfection
with siRNA (Fig. 2a and b). There was a concomitant
and significant decline in cell migration (42.3%) (Fig. 2c),
but not cell invasion (Fig. 2d) when compared to siNeg
cells, although a downward trend was observed for cell
invasion upon YBX1 silencing.Fig. 3 Global gene expression profiling in YB-1 silenced MDA-MB-231 cells
Human Transcriptome 2.0 Array. a Hierarchical clustering and b Volcano pl
and fold change <−2 and >2. c Enrichment score of functional annotationGlobal gene expression profiling identified CORO1C as a
potential downstream target of YB-1
To identify potential targets of the YB-1 protein, and to
unravel the molecular mechanism underlying the ob-
served phenomena upon silencing of the YBX1 gene,
global gene expression profiling using the Affymetrix
GeneChip® Human Transcriptome 2.0 Array was carried
out in the YBX1 silenced MDA-MB-231 cells. Using a
cut off value of <−2 and >2 and p value of <0.05, a total
of 8 coding genes were found to be up-regulated and 12
coding genes (excluding YBX1) were down-regulated in
the siYB-1 MDA-MB-231 cells when compared to siNeg
cells (Fig. 3a and b), which included both the annotated. Gene expression profiling was carried out using Affymetrix GeneChip®
ot of the differentially expressed genes using a cut-off value of p < 0.05
clustering using DAVID analysis
Table 1 List of differentially expressed annotated coding genes
Down-regulated genes Up-regulated genes
Gene symbol Fold change (siYB-1 vs. siNeg) p value Gene Symbol Fold change (siYB-1 vs. siNeg) p value
YBX1 -6.99 0.000004 PTGES 2.04 0.038408
KATNAL1 -4.16 0.000009 CDKN1B 2.15 0.014217
IFI6 -3.63 0.000034 HIPK3 2.2 0.00001
SLC9A3R2 -3.15 0.000483 SRGAP1 2.24 0.006231
TYW3 -2.58 0.000243 LMLN 2.33 0.027208
SLAIN2 -2.54 0.000012 KRTAP2–2 2.34 0.009131
TMEM33 -2.52 0.008867 TMEM160 2.75 0.014184






Fig. 4 Coronin-1C protein expression is dependent on YB-1 protein expression. a Coronin-1C protein expression was decreased when YB-1 was
knocked down in MDA-MB-231 cells. b Coronin-1C protein expression was increased when YB-1 protein was overexpressed in MDA-MB-231 cells.
Error bar = SEM, **p < 0.01, indicates statistically significant difference. Representative samples of Western blots are shown as well
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Lim et al. BMC Cancer  (2017) 17:201 Page 8 of 15non-coding and coding genes. Table 1 shows the list of
annotated coding genes that were differentially
expressed. Additional file 2: Table S2 shows three non-
coding genes that were differentially expressed.
To validate the accuracy of the microarray data, expres-
sion of the highest differentially expressed genes was
quantitated by qPCR. All the genes analyzed showed a
consistent pattern with the microarray results (Additional
file 3: Figure S1a), suggesting that the microarray data was
highly reliable and reproducible. DAVID analysis of the
differentially regulated genes identified these genes as
highly enriched for cytoskeleton (Fig. 3c), suggesting thatFig. 5 Coronin-1C is a downstream target of YB-1. a Gene expression of CO
upon silencing of YBX1 or CORO1C. c Representative images of Western blo
decrease in CORO1C gene or protein expression upon silencing of CORO1C
contrast, YBX1 gene and protein expression were decreased in siYB-1 MDA-
target of YB-1. Error bar = SEM, *p < 0.05, **p < 0.01, ***p < 0.001, indicateYB-1 protein could participate in the regulation of cyto-
skeletal structures, leading to changes in cell migration or
invasion, which corroborates with the results obtained.
Subsequently, the protein expression of some differen-
tially expressed genes, which have been shown to be in-
volved in cancers and may play a role in migration and
invasion in breast cancer, was screened by Western blot
in YBX1 silenced MDA-MB-231 cells (Additional file 3:
Figure S1b), and coronin-1C was then selected for fur-
ther investigation. The protein expression of coronin-1C
was found to be decreased when YB-1 was silenced
(Fig. 4a and Additional file 3: Figure S1b). Conversely,RO1C upon silencing of YBX1 or CORO1C. b Gene expression of YBX1
t showing the expression of coronin-1C and YB-1 proteins. There is a
or YBX1 when compared to siNeg cells in MDA-MB-231 cell line. In
MB-231 cells only, indicating that coronin-1C is a likely downstream
s statistically significant difference
Fig. 6 CORO1C is an indirect target of YB-1. a Gaussia luciferase re-
porter assay revealed no significant difference in the average relative
luminescence signal (RLU) between cells co-transfected with CORO1C
promoter construct and siNeg or siYB-1 cells. b Gaussia luciferase re-
porter assay showed no significant difference in average RLU between
the cells co-transfected with CORO1C promoter construct and YB-1
ORF plasmid or empty vector backbone. These results indicate that YB-
1 does not bind directly to the CORO1C promoter. Error bar = SEM,
**p < 0.01, ***p < 0.001, indicates statistically significant difference
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a modest increase in coronin-1C expression (Fig. 4b),
suggesting that coronin-1C is likely to be a downstream
target of YB-1 protein. While down-regulation of YB-1
alone reduced expression of the CORO1C gene and pro-
tein concomitantly (Fig. 5a and c), knockdown of
CORO1C alone did not alter the gene and protein ex-
pression of YB-1 (Fig. 5b and c), further validating that
coronin-1C is a downstream target of YB-1.
To determine whether YB-1 directly regulates CORO1C
at the transcriptional level, the Gaussia luciferase reporter
assay was performed. However, there was no reduction in
luciferase signal after YB-1 silencing (Fig. 6a). The RLU
signal was found to be significantly increased upon co-
transfection of the CORO1C promoter reporter construct
with both the YB-1 ORF plasmid or empty vector
backbone in contrast to co-transfection of the nega-
tive promoter construct with the YB-1 ORF plasmid
in MDA-MB-231 cells (Fig. 6b). Hence, the results
suggest that YB-1 does not regulate transcription of
CORO1C in a direct manner.
The same biological effect was also elicited in Hs578T
cells, whereby silencing of the YBX1 gene in Hs578T
cells also resulted in a concomitant decrease in the gene
(54.3%) and protein expression of coronin-1C (66.9%)
(Fig. 7a–c) but knockdown of CORO1C alone did not
alter the protein expression of YB-1 (Fig. 7d).
siRNA- mediated silencing of CORO1C inhibits cell
migration and invasion
Silencing of CORO1C induced a significant decrease in
cell migration (52.6%) (Fig. 8a) and cell invasion (63.9%)
(Fig. 8b) in MDA-MB-231 breast cancer cells. Similar
findings were also observed in siCORO1C-treated
Hs578T cells (Fig. 9).
siRNA-mediated YB-1- silencing in CORO1C overexpressing
cells decreased cell migration and invasion
To further substantiate the notion that YB-1 could regu-
late cell migration and invasion through coronin-1C, a
rescue experiment was carried out by silencing YBX1 in
CORO1C overexpressing MDA-MB-231 cells. Coronin-
1C overexpression induced a marked increase in cell
migration and invasion (Fig. 10), which were attenuated
Fig. 7 YB-1 silencing decreased coronin-1C expression in the highly invasive Hs578T breast cancer cell line. a-b CORO1C gene level and protein
expression of coronin-1C decreased when YBX1 was knocked down in Hs578T cells. c-d Protein expression of coronin-1C and YB-1 in either
CORO1C or YB-1 silenced Hs578T cells. Error bar = SEM, *p < 0.05, **p < 0.01, indicates statistically significant difference
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pressing cells.
Discussion
Metastasis, the leading cause for cancer related deaths,
is regulated by diverse molecular pathways in cancer
cells and involves a complex multi-step process collect-
ively termed as the ‘invasion-metastasis cascade’ [2]. YB-
1 has been found to promote a metastatic phenotype in
breast cancer [17], gastric cancer [7, 18] and prostate
cancer [19]. Moreover, YB-1 has been suggested to be an
independent predictor of liver metastasis and relapse in
patients with advanced gastric cancer [18]. In addition,
YB-1 is overexpressed in the majority of triple-negative
breast cancers (TNBC), which belongs to a highly ag-
gressive subtype of breast cancer [20]. Hence, to obtain
a better understanding of the functional role(s) of YB-1in breast cancer metastasis, the YBX1 gene was knocked
down in two highly aggressive TNBC cell lines, namely
MDA-MB-231 and Hs578T cells. Knockdown of YB-1 in
MDA-MB-231 cells led to a decrease in both the migra-
tion and invasive potential of the breast cancer cells.
Our results are in line with a previous study where YB-1
was observed to mediate migratory and invasive proper-
ties of MDA-MB-231 cells [17].
Gene expression profiling in YBX1 silenced MDA-
MB-231 cells was performed to identify potential targets
of YB-1 that are important in metastasis. Interestingly,
from the functional annotation clustering of the differen-
tially expressed genes, cytoskeleton proteins were found
to be highly enriched. One of the fundamental steps for
metastasis is the ability of cancer cells to migrate or in-
vade, which is driven by actin re-modelling, formation of
protrusions and cell adhesion that are mediated by
Fig. 8 CORO1C silencing in MDA-MB-231 cells reduced cell migration and invasion. a-b Cell migration and invasion were significantly inhibited in
the siCORO1C-treated MDA-MB-231 cells. Error bar = SEM, *p < 0.05, ***p < 0.001, indicates statistically significant difference. Representative fields
of the migration and invasion assay at 10X magnification are shown as well (Scale bar =100 μm)
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several proteins such as N-WSAP, Arp2/3 complex, cofi-
lin and coronins [22, 23]. The role of actin re-modelling
and its regulators in cancer metastasis has been widely
studied [24, 25]. Nevertheless, much remains to be eluci-
dated with regard to the exact mechanisms or genes that
regulate actin re-modelling, resulting in acquisition of
migratory or invasive abilities by cancer cells, a key step
in cancer metastasis. Furthermore, the YB-1 protein has
been observed to bind to actin and tubulin, and promote
microtubule assembly [26]. YB-1 may therefore regulate
different structural components of the cytoskeleton.
Our results showed that the expression of coronin-1C
was dependent on the expression of YB-1 but not vice-
versa (in both MDA-MB-231 cells and Hs58T cells), sug-
gesting that coronin-1C is a likely downstream target of
YB-1. Coronin-1C (also known as Coronin 3) is a mem-
ber of the coronin family of actin-binding proteins that
regulate re-modelling of actin filaments and thus control
cell migration which relies on actin dynamics [27, 28].
Coronins are known to co-localise with F-actin [29].
They recruit Arp2/3 complex to ATP-F-actin, and in-
hibit cofilin, thus preventing disassembly at the fast
growing ends (plus end) of cells, and facilitatingassembly of actin filaments. However, coronins also re-
cruit cofilin to the slow growing ends (minus end), with
the opposite effect of favoring disassembly of actin fila-
ments [30]. These mechanisms result in elongation of
the cell membrane at the leading edge, and retraction of
the cells at the rear-end, thereby facilitating cell migra-
tion and even invasion.
As we were interested in metastasis-related proteins,
we focused on proteins highly enriched for cytoskeleton-
related function as shown by the DAVID functional an-
notation analysis. Coronin-1C was selected for further
investigation as this protein has been associated with
metastasis in a variety of cancers, including breast can-
cer [31] and other malignancies such as lung [32], dif-
fuse glioma [29], hepatocellular carcinoma [33] and
gastric cancer [25]. Furthermore, expression of coronin-
1C which is known to be highest in the TNBC subtype,
has been reported to correlate with lower survival [31].
Recently, microRNA-206 (miR-206) was found to re-
duce cell migration in MDA-MB-231 and SUM159
TNBC cell lines, by regulating the expression of its tar-
get gene, coronin-1C [31]. Moreover, overexpression of
coronin-1C was found to correlate with lymph node
spread and increased clinical stage in gastric carcinoma,
Fig. 9 CORO1C silencing in Hs578T cells inhibited cell migration and invasion. a-b Cell migration and invasion were significantly reduced in
siCORO1C-treated Hs578T cells. Error bar = SEM, **p < 0.01. Representative fields of the migration and invasion assay at 10X magnification are
shown as well (Scale bar =100 μm)
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[25]. In diffuse glioma, silencing of coronin-1C led to re-
duced invadopodia formation, migration and invasion
[24]. Taken together, these findings suggest the import-
ance of elevated coronin-1C in tumour progression and
metastasis. The other interesting differentially expressed
genes that were found to be enriched for cytoskeleton-
related function as analysed by DAVID in this present
study, were CALDI, KRTAP2–2 and KRTAP2–3. CALDI,
which encodes for caldesmon, a versatile protein that
binds to actin, myosin, calmodulin and tropomyosin, is in-
volved in cell motility [34] and regulates metastasis of gas-
tric cancer [35]. KRTAP2–2 and KRTAP2–3 belongs to
the hair keratin–associated proteins (KRTAPs) family
which form major structural components of the hair shaft
with no known function in cancer cells [36]. Another dif-
ferentially expressed gene identified, encodes the Rho
GTPase activating protein, which is also known to be in-
volved in the regulation of cell motility and cytoskeletal
dynamics [37]. It may therefore be compelling to deter-
mine the association of YB-1 with these genes and their
roles in breast cancer metastasis.
To the best of our knowledge, this is the first time that
YB-1 has been demonstrated to drive breast cancer me-
tastasis (cell migration and/or invasion) via coronin-1C.Silencing of YB-1 or coronin-1C in MDA-MB-231 cells
resulted in decreased cell migration and cell invasion,
suggesting that YB-1 regulates these cellular processes
via coronin-1C. Moreover, we observed a similar pheno-
type upon YBX1 silencing in the invasive Hs578T cells,
including significant reduction in cell migration and a
downward trend for cell invasion (although not signifi-
cant). The latter observation could be due to the differ-
ent gene expression profiles of the two cell lines as
MDA-MB-231 cells are derived from an adenocarcinoma
while Hs578T cells are derived from a carcinosarcoma
[38]. In addition, the decrease in cell migration and inva-
sion observed upon YB-1 silencing in coronin-1C over-
expressed cells, further confirmed our hypothesis that
YB-1 plays an important role in regulating cell migration
and invasion through regulation of coronin-1C expres-
sion. The luciferase reporter assay revealed that coronin-
1C is an indirect target of YB-1, suggesting that other
intermediary proteins may also be involved. It is worth
noting that some of the differentially expressed genes
from the microarray analysis included non-coding genes
such as long non-coding RNA. A previous report has
found that non-coding RNAs such as microRNAs are
directly involved in the transcriptional regulation of
coronin-1C in breast cancer [31]. As non-coding genes
Fig. 10 a-b Silencing of YBX1 gene in coronin-1C overexpressing MDA-MB-231 cells decreased cell migration and invasion. Error bar = SEM,
*p < 0.05, ***p < 0.001. Representative fields of the migration and invasion assay at 10X magnification are shown (Scale bar =100 μm)
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ther evaluate in-depth the roles of these genes. Several
studies have also shown that silencing CORO1C de-
creases both cell invasion and migration [24, 25, 29, 32],
which is consistent with our findings, thus suggesting its
therapeutic and prognostic potential.Conclusion
In conclusion, the association between YB-1 and
coronin-1C provides a novel pathway which could be a
potential therapeutic target in breast cancer metastasis.
Overexpression of YB-1 and coronin-1C observed in
TNBC suggests the need for more comprehensive
Lim et al. BMC Cancer  (2017) 17:201 Page 14 of 15investigation of this association. Future identification of
intermediate proteins that are involved in YB-1 regulated
coronin-1C could provide further biological insights re-
garding the metastatic cascade, with the possibility of
identifying reliable biomarkers of early metastasis.
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